Skip to main content
Fig. 1 | Trials

Fig. 1

From: A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Fig. 1

Study design and five different treatment arms. DZD, delpazolid; BDM, bedaquiline, delamanid, moxifloxacin; QD, once daily; BID, twice daily; SCC, sustained culture conversion to negative; WK08, treatment week 08; HR, isoniazid – rifampicin; NTP, national TB programme

Back to article page

Trials

ISSN: 1745-6215